FORM 51-102F3
NATIONAL INSTRUMENT 51-102
MATERIAL CHANGE REPORT UNDER SECTION 7.1 OF NI 51-102

FILED VIA SEDAR

Item 1. Name and Address of Company

MPX International Corporation ("**MPXI**" or the "**Company**")
5255 Yonge Street, Suite 701
Toronto, ON M2N 6P4

Item 2. Date of Material Change

A material change took place on July 16, 2019.

Item 3. News Release

On July 16, 2019, a news release in respect of the material change was released by telecopier through the facilities of Accesswire.

Item 4. Summary of Material Change

On July 16, 2019, the Company announced that it completed the previously announced acquisition of a 20% stake in 2702148 Ontario Inc. dba KAAJENGA Cannabis ("**KAAJENGA Cannabis**"), securing the exclusive rights to a turnkey video learning and engagement platform for the Cannabis Industry (the "**Cannabis Kiosk Solution**").

MPXI also entered into definitive buy/sell agreements from the shareholder of KAAJENGA Cannabis to acquire all remaining shares of the company based on achieving specific patient acquisition milestones in exchange for no less than 2,900,000 common shares and common share purchase warrants.

Item 5. Full Description of Material Change

On July 16, 2019, the Company announced that it completed the previously announced acquisition of a 20% stake in 2702148 Ontario Inc. dba KAAJENGA Cannabis ("**KAAJENGA Cannabis**"), providing MPXI with an exclusive, worldwide, perpetual, royalty-free licence to use KAAJENGA technology for the purpose of developing and commercializing the Cannabis Kiosk Solution.

MPXI also entered into definitive buy/sell agreements from the shareholder of KAAJENGA Cannabis to acquire all remaining shares of the company based on achieving specific patient acquisition milestones in exchange for no less than 2,900,000 common shares and common share purchase warrants.

MPXI's initial investment comprised $125,000 in cash and issued 245,048 units (the "**Units**") at a price of $0.51 per Unit comprising one (1) common share in the capital of the MPXI Shares ("**Common Share**") and one (1) common share purchase share warrant ("**Warrant**"). Each Warrant entitles the holder to purchase one (1) Common Share ("**Warrant Shares**") at an exercise price of $0.61 per Warrant Share for five (5) years from the date of issuance.

This investment provides MPXI with compliant patient, doctor and healthcare practitioner education and provides MPXI with a unique mechanism for supporting patient communities. The learning will be delivered through a kiosk that will engage and educate patients and provide a process to fulfill prescriptions for medical cannabis, all in a manner compliant with the *Cannabis Act* (Canada) (the "**Cannabis Act**").

Item 6. **Reliance on Section 7.1(2) of National Instrument 51-102**

The report is not being filed in reliance on section 7.1(2) of National Instrument 51-102.

Item 7. **Omitted Information**

No information has been omitted.

Item 8. **Executive Officer**

W. Scott Boyes, Chairman, President, Chief Executive Officer and Director
416-840-4703

Item 9. **Date of Report**

July 25, 2019